Access To Medicine Foundation

Often searched

Index ranking

Vacancies

10 year analysis

  • Healthcare inequity
    • How big is the problem?
    • How we drive change
    • Our story
    • Our impact
    • How big is the problem?
    • How we drive change
    • Our story
    • Our impact
  • Become a catalyst
    • Investors
    • Companies
    • Government & policymakers
    • Events & engagements
    • Investors
    • Companies
    • Government & policymakers
    • Events & engagements
  • Sectors and research
    • R&D-based pharma companies
    • Medical gas companies
    • Generic medicine manufacturers
    • Diagnostics companies
    • Vaccine manufacturers
    • Research hub
    • Company profiles & report cards
    • R&D-based pharma companies
    • Medical gas companies
    • Generic medicine manufacturers
    • Diagnostics companies
    • Vaccine manufacturers
    • Research hub
    • Company profiles & report cards
  • Cross-Sector Programmes
    • Antimicrobial resistance
    • Diabetes care
    • Antimicrobial resistance
    • Diabetes care
  • On the pulse of global health
    • Access insights
    • The Health Equity podcast
    • Access insights
    • The Health Equity podcast
  • News
  • Our team
  • Featured insights
  • Governance & financials
  • Vacancies
  • Media coverage
  • FAQ
  • Contact us

Date

01 June 2018

‘Tekorten antibiotica gevolg van monopolie op grondstoffen’, reports NOS

"More and more frequently occurring shortages of commonly used antibiotics are the result of monopolies or near-monopolies of the raw material producers" - Rinke van den Brink covers the Foundation's new white paper on antibiotic shortages.

Rinke van den Brink reports on the Foundation's new white paper about antibiotic shortages: "The increasingly frequent shortages of commonly used antibiotics are the result of monopolies or near-monopolies of the raw material producers ... According to Access to Medicine, pharmaceutical companies have little interest in to make the production and distribution chain for antibiotics more reliable. These are medicines that make relatively little money. They are cheap compared to many other means. Moreover, the demand is increasing in poor countries.

The white paper is titled 'Shortages, stockouts and scarcity: the issues facing the security of antibiotic supply and the role of pharmaceutical companies.' 

Access to Medicine Foundation

Interested in our work?

Access to Medicine Foundation is funded by

Terms & conditions

Privacy & cookie policy

Disclaimer

Copyright 2004 - 2025 Access to Medicine Foundation - All Rights Reserved